• Other
  • Exited

True North Therapeutics is a biotechnology company developing novel therapies that selectively target the Complement pathway of the immune system to address fundamental mechanisms in diseases with high unmet need, including rare diseases. The company’s lead monoclonal antibody drug candidate, TNT009, selectively inhibits a target in the Classical Complement pathway, thereby preventing downstream disease processes involving phagocytosis, inflammation, and cell lysis.

truenorthrx.com